Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 215,477 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 88,424 · Balance 215,477 F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 88,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000086 · wk-form4_1782160342.xml · nonDerivative · entry 1 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,477 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 44,031 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001601830-25-000111 · wk-form4_1750713807.xml · derivative · entry 2 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,031 Underlying: Class A Common Stock · 44,031 shares Expires 2035-06-18 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 22,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000111 · wk-form4_1750713807.xml · nonDerivative · entry 1 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,053 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 82,781 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · derivative · entry 8 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,781 Underlying: Class A Common Stock · 82,781 shares Expires 2034-11-21 F11 · derivative.exercise_date: Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 17,694 | Not disclosed Strike: $6.64 | Not disclosed |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · derivative · entry 7 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,694 Underlying: Class A Common Stock · 17,694 shares Expires 2034-05-14 F10 · price: Received in the Transaction in exchange for a share option to acquire 22,894 Exscientia ordinary shares for $5.13 per share. F9 · derivative.exercise_date: Options vest and become exercisable on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 15,286 | Not disclosed Strike: $7.34 | Not disclosed |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · derivative · entry 6 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,286 Underlying: Class A Common Stock · 15,286 shares Expires 2033-05-16 F8 · price: Received in the Transaction in exchange for a share option to acquire 19,778 Exscientia ordinary shares for $5.67 per share. F7 · derivative.exercise_date: Options vest and become exercisable on May 17, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 30,670 | Not disclosed Strike: $6.59 | Not disclosed |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · derivative · entry 5 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,670 Underlying: Class A Common Stock · 30,670 shares Expires 2033-05-02 F6 · price: Received in the Transaction in exchange for a share option to acquire 39,683 Exscientia ordinary shares for $5.09 per share. F5 · derivative.exercise_date: Options vest and become exercisable in equal quarterly installments over a three year period beginning May 3, 2023, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 41,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · nonDerivative · entry 4 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,037 F4 · kind: Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 17,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · nonDerivative · entry 3 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,647 F3 · shares: Represents RSUs that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs will vest onMay 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 15,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · nonDerivative · entry 2 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,953 F2 · shares: Represents restricted stock units ("RSUs") that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs vest in equal quarterly installments beginning on November 3, 2024 and continuing through May 3, 2026, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 30,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001601830-24-000221 · wk-form4_1732317944.xml · nonDerivative · entry 1 Michor Franziska · CIK 0002045159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,618 F1 · price: (1) Received in exchange for [] ordinary shares of Exscientia plc ("Exscientia") in connection with the acquisition of the entire issued and to be issued share capital of Exscientia by Recursion Pharmaceuticals, Inc. ("Recursion") on November 20, 2024 (the "Transaction"). The last closing price on The Nasdaq Stock Market prior to the effective time of the Transaction of (a) the American Depositary Shares ("ADSs") representing ordinary shares of Exscientia was $4.84 per ADS, and (b) Recursion's Class A common stock was $6.27 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.